Citi Lifts Bristol-Myers Squibb Price Target, Citing Improved Biopharma Outlook Through 2026
Citi analyst Geoff Meacham raised his price target on Bristol-Myers Squibb (BMY) to $60, citing a more favorable setup for the sector. The move comes as the drugmaker also announces a partnership with Microsoft to leverage AI for earlier lung cancer detection.